Patients diabétiques en dialyse péritonéale

Auteurs

  • yassine Allata 1. Department of Nephrology, Hemodialysis and Transplantation, Hassan II University Hospital, Fez, Morocco. https://orcid.org/0000-0002-0999-0640
  • Basmat Amal Chouhani 1. Department of Nephrology, Hemodialysis and Transplantation, Hassan II University Hospital, Fez, Morocco. 2. Epidemiology and Health Sciences Research Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez, Morocco. https://orcid.org/0000-0002-9687-1390
  • Ghita EL Bardi 1. Department of Nephrology, Hemodialysis and Transplantation, Hassan II University Hospital, Fez, Morocco. 2. Epidemiology and Health Sciences Research Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez, Morocco. https://orcid.org/0000-0002-2673-7137
  • Tarik Sqalli Houssaini 1. Department of Nephrology, Hemodialysis and Transplantation, Hassan II University Hospital, Fez, Morocco. 2. Epidemiology and Health Sciences Research Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez, Morocco. https://orcid.org/0000-0002-7388-288X
  • Nadia Kabbali 1. Department of Nephrology, Hemodialysis and Transplantation, Hassan II University Hospital, Fez, Morocco. 2. Epidemiology and Health Sciences Research Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez, Morocco. https://orcid.org/0000-0003-1546-5321

DOI :

https://doi.org/10.25796/bdd.v6i3.76653

Mots-clés :

Diabète, complication mécanique, péritonite, dialyse péritonéale, insuffisance rénale

Résumé

Pour le texte complet cliquer sur l'icone pdf ou sur https://bdd.rdplf.org/index.php/bdd/article/view/76653/72083

La prévalence du diabète sucré chez les patients nécessitant une thérapie de remplacement rénal est en hausse dans le monde entier, et le diabète est désormais la principale cause d'insuffisance rénale chronique terminale (IRCT) chez environ un tiers de ces patients. Bien que la transplantation rénale soit le traitement optimal pour l'IRCT, sa disponibilité limitée a conduit à l'utilisation généralisée de l'hémodialyse en centre (HD) comme modalité de remplacement rénal par défaut dans de nombreux pays. Cependant, pour les patients diabétiques, la dialyse péritonéale (DP) peut offrir une option supérieure en raison de son taux d'ultrafiltration plus lent, qui peut aider à diminuer les complications associées à la circulation extracorporelle pendant l'HD. Malheureusement, des préoccupations infondées concernant l'échec technique et l'augmentation des taux de complications ont dissuadé certains cliniciens de recommander la DP comme traitement de première intention pour les patients diabétiques en IRCT.

Nous avons mené une étude rétrospective comparant l'incidence des complications et les taux de survie technique entre les patients diabétiques et non diabétiques bénéficiant de la DP dans une unité de dialyse au Maroc. Nos résultats révèlent que les patients diabétiques en DP n'ont pas connu de différence significative en termes de survie de la technique ou d'incidence de complications par rapport aux non diabétiques. Cependant, nous avons constaté que seule une petite proportion (17,5 %) des patients de notre unité de DP était diabétique, ce qui suggère que l'accès à la DP pour les patients diabétiques atteints d'ESRD doit être amélioré.

Introduction

The number of patients with diabetes mellitus (DM) who require renal replacement therapy (RRT) has increased globally. DM is now the leading cause of end-stage renal disease (ESRD), accounting for about one-third of all patients initiating RRT worldwide. ESRD poses a significant public health challenge and requires substantial resources, in terms of both finances and human capital[1]. In Morocco, diabetes accounts for 32.8% of all cases of renal failure[2]. While renal transplantation is the preferred treatment for ESRD, limited access has resulted in dialysis, mainly in-center hemodialysis (HD), being used in most countries[1]. However, Hong Kong, the Jalisco region of Mexico, and Guatemala have implemented peritoneal dialysis (PD) as the first-line treatment, with 71%, 61%, and 57% of ESRD patients receiving PD, respectively. The global rise in the number of ESRD patients is making it increasingly challenging for low- and middle-income countries to provide adequate dialysis access[3].

Peritoneal dialysis presents numerous benefits in comparison to hemodialysis and is therefore an appealing alternative. PD offers slow and sustained ultrafiltration, which is particularly beneficial for patients with multiple cardiovascular comorbidities, such as those with diabetes[4]. It reduces the risks associated with rapid ultrafiltration during HD, such as intradialytic hypotension, myocardial ischemia, and cardiac arrhythmias. PD also helps preserve residual renal function (RRF), which is especially important for diabetic patients. Moist et al.[5]found that PD patients had a 65% lower RRF loss than HD patients. Other benefits of PD include greater patient autonomy, reduced incidence of diabetic retinopathy flare-ups, lower doses of erythropoietin-stimulating agents to achieve hemoglobin goals, and a lower risk of contracting certain transmissible diseases, such as hepatitis C[6]. Despite these advantages, and the equivalent survival rates of PD and HD[7], patients with diabetes are typically referred to HD, regardless of medical evidence or patient preference.

The aim of this study was to analyze our PD unit’s experience with peritoneal dialysis treatment for diabetics and compare the incidence of complications and the technique survival rates to those of non-diabetic patients.

Methods

We conducted a retrospective study that included all incident adult patients starting peritoneal dialysis at our dialysis unit in the Department of Nephrology at Hassan II University Hospital of Fez from January 2018 to December 2022.

This region, also called the Fez-Meknes region, is one of the 12 new regions of Morocco established by the 2015 territorial division. It covers an area of over 40,000 Km² and has a population of over 4.2 million people[8]. This region has seen a rapid increase in the number of hemodialysis units. In 2021, there were 51 hemodialysis centers; however, there was only one peritoneal dialysis center, located at our university hospital.

To identify diabetic patients, we used the diagnostic criteria of fasting blood glucose levels of ≥ 1.26 g/L or blood glucose levels of ≥ 2.00 g/L two hours after a glucose load[9].

Blood glucose levels were closely monitored and managed through a combination of dietary adjustments and sub-cutaneous insulin therapy, as indicated.

Peritoneal dialysis catheter insertion was performed by a nephrologist using mini-laparotomy under local or loco-regional anesthesia. A two-week observation period preceded dialysis initiation.

Peritoneal dialysis prescriptions for diabetic patients were individualized based on factors such as residual renal function, adequacy of dialysis, and fluid balance.

Dialysis was initiated for diabetic patients with the Continuous Ambulatory Peritoneal Dialysis (DPCA) method, utilizing Dianeal 1.36% solution. This method involved three exchanges daily, with an empty abdomen at night to facilitate adequate drainage and fluid balance. As patients progressed, a transition to Dialysis Prescription Automated Peritoneal Dialysis (DPA) was proposed. Under the DPA regimen, all eligible patients were transitioned to using a cycler. The DPA protocol entailed utilizing the Dianeal 1.36% solution for nightly dialysis sessions lasting 8-9 hours, allowing for four to five cycles. No Icodextrin or other non-glucose dialysat was used, due to their unavailability. The use of Dianeal 2.27% was limited to short periods to optimize fluid balance.

Our patients attended regular follow-up appointments with a multidisciplinary team comprising nephrologists, endocrinologists, dietitians, and diabetes educators. This collaborative approach ensured comprehensive oversight of each patient’s medical condition and allowed for timely adjustments to their treatment plans as needed.

We collected the data from the patients’ medical records, which were then processed using Microsoft Excel.

The statistical analysis employed in this study involved a comparison between diabetic and non-diabetic patients, with a specific focus on the incidence of complications and the technique survival rate. To achieve this, a combination of Kaplan-Meier survival analysis and the Cox proportional hazards model was utilized.

The Kaplan-Meier survival analysis was utilized to estimate and compare the technique survival rates of diabetic and non-diabetic patients. The log-rank test associated with the Kaplan-Meier analysis was applied to assess the statistical significance of differences observed between the two groups.

In addition, both bivariate and multivariate analyses using the Cox proportional hazards model were employed to perform a more refined assessment of the impact of diabetes technique survival while accounting for potential confounding factors. Covariates such as age, gender, and Charlson Comorbidity Index were considered in the model to adjust for their potential influence.

Results

The study included 80 patients who underwent PD, with a mean age of 47 +/-17 years and a sex ratio of 1.1 M/F. The main etiologies of ESRD were hypertension, glomerular nephropathies, diabetes, and polycystic

.....

Références

Thurlow JS, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52:98-107. 10.1159/000514550. DOI: https://doi.org/10.1159/000514550

Benghanem Gharbi M, Elseviers M, Zamd M, et al. Maladie rénale chronique, hypertension, diabète et obésité dans la population adulte du Maroc : comment éviter le «sur»- et le «sous-»-diagnostic de l’IRC. Kidney Int. 2016;89:1363-71. 10.1016/j.kint.2016.02.019. DOI: https://doi.org/10.1016/j.kint.2016.02.019

Niang A, Iyengar A, Luyckx VA. Hemodialysis versus peritoneal dialysis in resource-limited settings. Curr Opin Nephrol Hypertens. 2018;27:463-471. 10.1097/MNH.0000000000000455. DOI: https://doi.org/10.1097/MNH.0000000000000455

Selby NM, McIntyre CW. Les effets cardiaques aigus de la dialyse. Semin Dial. 2007;20:220-8. 10.1111/j.1525-139X.2007.00281.x. DOI: https://doi.org/10.1111/j.1525-139X.2007.00281.x

Mathew AT, Fishbane S, Obi Y, et al. Préservation de la fonction rénale résiduelle chez les patients hémodialysés : revivre un vieux concept. Kidney Int. 2016;90:262-271. 10.1016/j.kint.2016.02.037. DOI: https://doi.org/10.1016/j.kint.2016.02.037

Cotovio P, Rocha A, Rodrigues A. Peritoneal dialysis in diabetics : there is room for more. Int J Nephrol. 2011;2011:914849. 10.4061/2011/914849. DOI: https://doi.org/10.4061/2011/914849

Wong B, Ravani P, Oliver MJ, et al. Comparaison de la survie des patients entre l’hémodialyse et la dialyse péritonéale parmi les patients éligibles pour les deux modalités. Am J Kidney Dis. 2018;71:344-351. 10.1053/j.ajkd.2017.08.028.

Site de la Direction Régionale de santé de Fès-Meknès. (2022). Consulté : 28 septembre 2022 : https://www.hcp.ma/region-fes/A-propos-de-la-direction_r8.html.

Charbonnel B, Le Feuvre C, et al. Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Diabetes Metab. 2004;30:2S2-2S8. DM-04-2004-30-2-C2-1262-3636-101019-ART1. DOI: https://doi.org/10.1016/S1262-3636(04)72798-6

Mehrotra R, Devuyst O, Davies SJ, et al. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27:3238-3252. 10.1681/ASN.2016010112. DOI: https://doi.org/10.1681/ASN.2016010112

Andrésdóttir G, Jensen ML, Carstensen B, et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care. 2014;37:1660-7. 10.2337/dc13-2036. DOI: https://doi.org/10.2337/dc13-2036

Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease : global dimension and perspectives. Lancet. 2013;382:260-72. 10.1016/S0140-6736(13)60687-X. DOI: https://doi.org/10.1016/S0140-6736(13)60687-X

Thomas MC, Cooper ME, Zimmet P. Évolution de l’épidémiologie du diabète de type 2 et des maladies rénales chroniques associées. Nat Rev Nephrol. 2016;12:73-81. 10.1038/nrneph.2015.173. DOI: https://doi.org/10.1038/nrneph.2015.173

Lindholm S, et al. Definition of metabolic syndrome in peritoneal dialysis. Perit Dial Int. 2009;29:S137-S144. https://pubmed.ncbi.nlm.nih.gov/19270203/ DOI: https://doi.org/10.1177/089686080902902S27

Blaine E, Tumlinson R, Colvin M, Haynes T, Whitley HP. Revue systématique de la littérature sur les ajustements de la dose d’insuline lors de l’initiation de l’hémodialyse ou de la dialyse péritonéale. Pharmacotherapy. 2022;42:177-187. 10.1002/phar.2659

Szeto CC, Kwan BC, Chow KM, et al. Metabolic syndrome in peritoneal dialysis patients : choice of diagnostic criteria and prognostic implications. Clin J Am Soc Nephrol. 2014;9:779-87. 10.2215/CJN.06620613. DOI: https://doi.org/10.2215/CJN.06620613

Soumis

2023-03-29

Accepté

2023-08-31

Publié

2023-11-13

Comment citer

1.
Allata yassine, Chouhani BA, EL Bardi G, Sqalli Houssaini T, Kabbali N. Patients diabétiques en dialyse péritonéale. Bull Dial Domic [Internet]. 13 nov. 2023 [cité 4 déc. 2025];6(3):105-12. Disponible sur: https://bdd.rdplf.org/index.php/bdd/article/view/76653